Identification
- Summary
Phosphoric acid is an ingredient used for electrolyte replenishment and total parenteral nutrition (TPN) therapy, and for the relief of upset stomach associated with nausea.
- Brand Names
- Freamine III 10, Hepatamine 8, Procalamine 3
- Generic Name
- Phosphoric acid
- DrugBank Accession Number
- DB09394
- Background
Phosphoric Acid is a colorless, odorless phosphorus-containing inorganic acid. Phosphoric acid is a sequestering agent which binds many divalent cations, including Fe++, Cu++, Ca++, and Mg++.
- Type
- Small Molecule
- Groups
- Approved
- Structure
Structure for Phosphoric acid (DB09394)
- Weight
- Average: 97.9952
Monoisotopic: 97.976895096 - Chemical Formula
- H3O4P
- Synonyms
- Not Available
- External IDs
- E 338
- E-338
- FEMA NO. 2900
- INS NO.338
- INS-338
- NSC-80804
- Y-11A06
Pharmacology
- Indication
Phosphoric acid is used in dentistry and orthodontics as an etching solution, to clean and roughen the surfaces of teeth where dental appliances or fillings will be placed.
Reduce drug development failure ratesBuild, train, & validate machine-learning modelswith evidence-based and structured datasets.Build, train, & validate predictive machine-learning models with structured datasets.- Associated Therapies
- Contraindications & Blackbox Warnings
Prevent Adverse Drug Events TodayTap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.Avoid life-threatening adverse drug events with our Clinical API- Pharmacodynamics
Transport of phosphate from the gut lumen is an active, energy-dependent process that is modified by several factors. ... Vitamin D stimulates phosphate absorption, an effect reported to precede its action on calcium ion transport.
- Mechanism of action
Phosphate supplementation of the diet of rodents has been shown to lead to reduction in the incidence of dental caries and different phosphates have different powers in reducing the cariogenic potential of the carbohydrates in a diet. Phosphate supplements seem to exert their cariostatic effect on the tooth surface either directly during eating or by excretion in the saliva.
- Absorption
Ortho phosphate is absorbed from, and to a limited extent secreted into, the gastrointestinal tract.
- Volume of distribution
Absorbed phosphoric acid is distributed widely in the body as phosphate. Increased serum phosphate concentrations have been reported rarely after phosphoric acid ingestion
- Protein binding
Not Available
- Metabolism
- Not Available
- Route of elimination
In adults, about two thirds of the ingested phosphate is absorbed, and that which is absorbed is almost entirely excreted into the urine.
- Half-life
In infants with normal renal function the serum half-life of phosphate following single oral or rectal overdose is 5-11 hours
- Clearance
Absorbed phosphate is filtered at the glomerulus and partially reabsorbed, with phosphate clearance 80 per cent of creatinine clearance.
- Adverse Effects
Improve decision support & research outcomesWith structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!Improve decision support & research outcomes with our structured adverse effects data.- Toxicity
Man: LDLo, route unreported at 220mg/kg Rabbit: LD 50, Route: Skin, Reported dose: 2740 mg /kg, Effects: Behavioral : somnolence ( general depressed activity), Excitement Rat: LC50, Route: inhalation, Reported dose: >850 mg/m3/1h Rat: LD50, Route: oral, Reported dose: 1530 mg/kg, Effects: Kidney, ureter and bladder hematuria, Behavioral: somnolence (general depressed activity)
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs Browse all" title="About SNP Mediated Effects/ADRs" id="snp-actions-info" class="drug-info-popup" href="javascript:void(0);">
- Not Available
Interactions
- Drug Interactions Learn More" title="About Drug Interactions" id="structured-interactions-info" class="drug-info-popup" href="javascript:void(0);">
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Drug Interaction Integrate drug-drug
interactions in your softwareAbacavir Abacavir may decrease the excretion rate of Phosphoric acid which could result in a higher serum level. Aceclofenac Aceclofenac may decrease the excretion rate of Phosphoric acid which could result in a higher serum level. Acemetacin Acemetacin may decrease the excretion rate of Phosphoric acid which could result in a higher serum level. Acetaminophen Acetaminophen may decrease the excretion rate of Phosphoric acid which could result in a higher serum level. Acetazolamide Acetazolamide may increase the excretion rate of Phosphoric acid which could result in a lower serum level and potentially a reduction in efficacy. - Food Interactions
- No interactions found.
Products
Drug product information from 10+ global regionsOur datasets provide approved product information including:dosage, form, labeller, route of administration, and marketing period.Access drug product information from over 10 global regions.- Mixture Products
Name Ingredients Dosage Route Labeller Marketing Start Marketing End Region Image Aminosyn Phosphoric acid (40 mg/100mL) + Alanine (448 mg/100mL) + Arginine (343 mg/100mL) + Glycine (448 mg/100mL) + Histidine (105 mg/100mL) + Isoleucine (252 mg/100mL) + Leucine (329 mg/100mL) + Lysine acetate (252 mg/100mL) + Magnesium acetate (21 mg/100mL) + Methionine (140 mg/100mL) + Phenylalanine (154 mg/100mL) + Potassium acetate (128 mg/100mL) + Proline (300 mg/100mL) + Serine (147 mg/100mL) + Sodium chloride (234 mg/100mL) + Threonine (182 mg/100mL) + Tryptophan (56 mg/100mL) + Tyrosine (31 mg/100mL) + Valine (280 mg/100mL) Injection, solution Intravenous Hospira, Inc. 2011-03-23 2017-11-01 US 
Anti Nausea Phosphoric acid (21.5 mg/5mL) + Dextrose, unspecified form (1.87 g/5mL) + Fructose (1.87 g/5mL) Liquid Oral Cardinal Health 2020-07-27 Not applicable US Anti Nausea Phosphoric acid (21.5 mg/5mL) + D-glucose monohydrate (1.87 g/5mL) + Fructose (1.87 g/5mL) Liquid Oral Medicine Shoppe International 2008-02-06 2013-06-09 US Anti Nausea Phosphoric acid (21.5 mg/5mL) + Dextrose, unspecified form (1.87 g/5mL) + Fructose (1.87 g/5mL) Liquid Oral H.E.B. 1995-11-22 2017-09-08 US Anti Nausea Phosphoric acid (21.5 mg/5mL) + Dextrose, unspecified form (1.87 g/5mL) + Fructose (1.87 g/5mL) Liquid Oral Rite Aid 1996-06-12 2017-11-04 US - Unapproved/Other Products
Name Ingredients Dosage Route Labeller Marketing Start Marketing End Region Image Anti Nausea Phosphoric acid (21.5 mg/5mL) + Dextrose, unspecified form (1.87 g/5mL) + Fructose (1.87 g/5mL) Liquid Oral Rite Aid 1996-06-12 2017-11-04 US Anti Nausea Phosphoric acid (21.5 mg/5mL) + D-glucose monohydrate (1.87 g/5mL) + Fructose (1.87 g/5mL) Liquid Oral Medicine Shoppe International 2008-02-06 2013-06-09 US Anti Nausea Phosphoric acid (21.5 mg/5mL) + Dextrose, unspecified form (1.87 g/5mL) + Fructose (1.87 g/5mL) Liquid Oral RUGBY LABORATORIES 2020-09-09 Not applicable US Anti Nausea Phosphoric acid (21.5 mg/5mL) + Dextrose, unspecified form (1.87 g/5mL) + Fructose (1.87 g/5mL) Liquid Oral H.E.B. 1995-11-22 2017-09-08 US Anti Nausea Phosphoric acid (21.5 mg/5mL) + Dextrose, unspecified form (1.87 g/5mL) + Fructose (1.87 g/5mL) Liquid Oral Kroger 2000-10-04 2017-11-01 US
Categories
- Drug Categories
- Chemical TaxonomyProvided by Classyfire
- Description
- This compound belongs to the class of inorganic compounds known as non-metal phosphates. These are inorganic non-metallic compounds containing a phosphate as its largest oxoanion.
- Kingdom
- Inorganic compounds
- Super Class
- Homogeneous non-metal compounds
- Class
- Non-metal oxoanionic compounds
- Sub Class
- Non-metal phosphates
- Direct Parent
- Non-metal phosphates
- Alternative Parents
- Inorganic oxides
- Substituents
- Inorganic oxide / Non-metal phosphate
- Molecular Framework
- Not Available
- External Descriptors
- phosphoric acids (CHEBI:26078)
- Affected organisms
- Not Available
Chemical Identifiers
- UNII
- E4GA8884NN
- CAS number
- 7664-38-2
- InChI Key
- NBIIXXVUZAFLBC-UHFFFAOYSA-N
- InChI
- InChI=1S/H3O4P/c1-5(2,3)4/h(H3,1,2,3,4)
- IUPAC Name
- phosphoric acid
- SMILES
- OP(O)(O)=O
References
- General References
- External Links
- Human Metabolome Database
- HMDB0002142
- KEGG Compound
- C00009
- PubChem Compound
- 1004
- PubChem Substance
- 347827839
- ChemSpider
- 979
- BindingDB
- 14671
- 8259
- ChEBI
- 26078
- ChEMBL
- CHEMBL1187
- Wikipedia
- Phosphoric_acid
Clinical Trials
- Clinical Trials Learn More" title="About Clinical Trials" id="clinical-trials-info" class="drug-info-popup" href="javascript:void(0);">
Phase Status Purpose Conditions Count 1, 2 Active Not Recruiting Treatment Myelodysplastic Syndrome 1 1, 2 Unknown Status Treatment Pancreatic Neoplasms 1 Not Available Completed Treatment Selective Enamel Etching in Dental Restorations 1
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
Form Route Strength Liquid Oral Liquid Dental Solution Oral Injection, solution Intravenous Gel Dental Solution Intravenous Solution Oral 750 mg/1 Gel Topical Liquid Dental; Topical Liquid Topical Injection Intravenous Injection Intravenous 0.21 g/100ml Solution Parenteral Paste Dental - Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Not Available
- Experimental Properties
- Not Available
- Predicted Properties
Property Value Source logP -1 Chemaxon pKa (Strongest Acidic) 1.8 Chemaxon Physiological Charge -2 Chemaxon Hydrogen Acceptor Count 4 Chemaxon Hydrogen Donor Count 3 Chemaxon Polar Surface Area 77.76 Å2 Chemaxon Rotatable Bond Count 0 Chemaxon Refractivity 14.65 m3·mol-1 Chemaxon Polarizability 5.81 Å3 Chemaxon Number of Rings 0 Chemaxon Bioavailability 1 Chemaxon Rule of Five Yes Chemaxon Ghose Filter No Chemaxon Veber's Rule No Chemaxon MDDR-like Rule No Chemaxon - Predicted ADMET Features
- Not Available
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
- Chromatographic Properties
Collision Cross Sections (CCS)
Adduct CCS Value (Å2) Source type Source [M-H]- 105.4215532 predictedDarkChem Lite v0.1.0 [M-H]- 117.37956 predictedDeepCCS 1.0 (2019) [M+H]+ 120.046234 predictedDeepCCS 1.0 (2019) [M+Na]+ 128.26027 predictedDeepCCS 1.0 (2019)
Drug created at November 30, 2015 19:10 / Updated at January 09, 2021 18:40